No Data
No Data
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)
NewAmsterdam Pharma (NAMS.US) Announces Phase 2 Trial Results of CETP Inhibitor Under Development Effectively Reduces “Bad Cholesterol” Levels
Recently, NewAmsterdam Pharma (NAMS.US) announced the results of its phase 2 trial of the CETP inhibitor obiceTrapib at the American College of Cardiology (ACC) in 2024. Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced that Prevail for its related Phase 3 key trial has reached recruitment9
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients With Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)
No Data